Clinical Outcomes in HER2-positive Lobular Breast Cancer: a Single-institution Experience

Purpose: Invasive lobular carcinomas (ILC), characterised by loss of the cell adhesion molecule E-cadherin, are typically oestrogen receptor (ER)-positive/HER2-negative luminal tumours with a similar prognosis to that expected for luminal invasive ductal carcinomas (IDC). Less than 5% of classical ILC but up to 35% of pleomorphic ILC are HER2-positive. Previous studies have suggested similar benefit from trastuzumab for HER2-positive ILC and IDC, but data are limited [1].

Source: Clinical Oncology - June 7, 2019 Category: Radiology Authors: T. Irfan, B. Asare, K. Mohammed, P. Osin, A. Nerurkar, I. Smith, M. Parton, S. Johnston, N. Turner, A. Okines Source Type: research